D. Boral Capital Reiterates “Buy” Rating for Medicus Pharma (NASDAQ:MDCX)

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report released on Monday,Benzinga reports. The firm currently has a $27.00 price objective on the stock.

Separately, Zacks Research upgraded shares of Medicus Pharma to a “hold” rating in a report on Monday, September 15th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.50.

Medicus Pharma Trading Down 3.4%

Shares of MDCX opened at $2.24 on Monday. The stock’s 50-day moving average price is $2.29 and its two-hundred day moving average price is $3.26. Medicus Pharma has a 12 month low of $1.79 and a 12 month high of $8.94. The company has a market capitalization of $39.92 million and a PE ratio of -1.67.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Equities research analysts predict that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in MDCX. Interchange Capital Partners LLC increased its position in Medicus Pharma by 14.0% in the 1st quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company’s stock valued at $6,182,000 after buying an additional 204,706 shares in the last quarter. Armistice Capital LLC acquired a new stake in Medicus Pharma in the first quarter valued at approximately $4,710,000. Guyasuta Investment Advisors Inc. bought a new stake in shares of Medicus Pharma during the second quarter valued at approximately $230,000. Private Advisor Group LLC acquired a new position in shares of Medicus Pharma during the first quarter worth approximately $211,000. Finally, SeaCrest Wealth Management LLC acquired a new position in shares of Medicus Pharma during the second quarter worth approximately $139,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.